EAPH may have a Big future,Any selling all depends on the news going forward at one time The news was this was going to be a Big CASH COW "see the old news story below" If they get it right this time the skys the limit:)
July 22, 2011 06:00 ET
Easton Pharmaceuticals Announces Projections of $15 Million in Revenue For 2012 From The Company's First Territory Launch of VIORRA in Mexico
VIORRA is a Female Over-The-Counter Aid for Treatment to Restore and Improve Vaginal Moisture and Elasticity Plus Increase Sexual Desire
TORONTO, ONTARIO--(Marketwire - July 22, 2011) - Easton Pharmaceuticals (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products has been advised of by BMV Medica S.A. de C.V. (BMV), the company that was recently retained in Mexico to finalize regulatory approval and arrange distribution partnerships for the company's first product launch in Mexico;
•BMV Medica S.A. de C.V. (BMV) has advised that their initial market analysis and conversations with distribution partnerships for the company's first product launch, VIORRA an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity, that also exhibits a very positive effect on women's sexual desire and arousal FSAD (Female Sexual Arousal Disorder) could generate upwards of $15 million dollars in revenue within twelve months of product launch.
•Mexico represents an ideal first territory launch site for our VIORRA Female Sexual Dysfunction (FSAD) product, stated John Easton, CEO and Chairman of the board of Easton Pharmaceuticals, "As Male Sexual Dysfunction products have historically done very well in Mexico, and with a population of 120 million, the raw numbers of prospective female customers are very attractive to Easton Pharmaceuticals. The world market for these female conditions are estimated in excess of $2 billion."
•BMV estimates the regulatory approval process will be completed in early 2012. In parallel with the regulatory filing, Easton Pharmaceuticals under the guidance of BMV has begun talks with several large distribution companies that are focused on sales and marketing in the women's health market. Easton Pharmaceuticals" believes that with both the regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of VIORRA and generate upwards of $15 million annual company revenue from Mexico beginning in 2012.
AI
